Mirum Pharmaceuticals

MIRM · NASDAQ

$85.07+$2.83 (+3.44%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $82.24

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Employees: 369
Headquarters: Foster City, California
Listed: Jul 18, 2019
Sector: Health Care
Industry: Biotechnology
Website: mirumpharma.com

Leadership

Mirum Pharmaceuticals executives
Name	Title	Since	Age
Michael Grey	—	2018	72
Peter Radovich	—	—	47
Christopher Peetz	—	2018	46
Eric Bjerkholt	—	—	65
Pamela Vig	—	—	53
Lara Longpre	—	—	54
Joanne Quan	—	—	61
Doug Sheehy	—	—	—
Laura Brege	—	—	67
Lon Cardon	—	—	59
William Fairey	—	—	60
Laurent Fischer	—	—	61
Patrick Heron	—	—	54
Saira Ramasastry	—	—	49
Timothy Walbert	—	—	58
Andrew Mckibben	—	2023	—

Revenue by product and region

Fiscal year ended Dec 31, 2024: $336.89M total revenue

By product

Total product sales, net$336.41M99.9%
License and other revenue$479.00K0.1%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Mirum Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Sanofi SAN.PA	Supplier and customer	FR	0.78
Pfizer PFE	Supplier and customer	US	0.39
Takeda Pharmaceutical	Supplier and customer	JP	0.36
Green Cross	Supplier and customer	KR	—
Satiogen Pharmaceuticals, Inc.	Supplier and customer	US	—
CANbridge Pharmaceuticals	Supplier and customer	CN	—

Similar companies

Companies in the same industry as Mirum Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.